Bacterial Immune System Blocks Viruses Without Killing the Host Cell

Antibiotic resistance is one of the most urgent threats in modern medicine, and bacteriophage therapy — using viruses to kill harmful bacteria — is emerging as a promising alternative. But understanding how bacteria defend themselves against phages is equally important, both for improving phage therapy and for uncovering fundamental principles of innate immunity. This study illuminates a key bacterial defense system called CBASS (Cyclic-oligonucleotide-based Anti-phage Signaling System) in ways that challenge long-held assumptions.

Researchers studied the CBASS pathway in Pseudomonas aeruginosa, a pathogen notorious for causing life-threatening infections in immunocompromised patients. CBASS detects phage infection and produces cyclic nucleotide signals that activate effector proteins to stop viral replication. A membrane-acting effector called CapV — a phospholipase enzyme — was widely presumed to work by inducing cell death, sacrificing the host to prevent viral spread.

The key finding overturns that model. When CBASS is constitutively activated — either by adding the signaling molecule 3',3'-cGAMP externally or by engineering continuous signaling — bacteria grow robustly, showing no fitness cost, while phage production is completely abolished. CapV selectively blocks a broad range of phages without harming the host.

Mechanistically, phages initially proceed normally: transcription occurs and early DNA replication begins. But phages fail to reach peak DNA levels and cannot package their DNA into stable capsids. The researchers propose that CapV disrupts capsid assembly at the inner membrane, a critical step in producing infectious phage particles.

This represents a fundamentally different immune strategy — containment rather than self-destruction. The implications extend beyond microbiology: understanding how bacteria neutralize phages without dying could help researchers engineer phage-resistant or phage-sensitive bacteria for therapeutic applications, and may offer conceptual models for designing antiviral strategies in higher organisms.